These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15334182)

  • 21. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The presenilins in Alzheimer's disease--proteolysis holds the key.
    Haass C; De Strooper B
    Science; 1999 Oct; 286(5441):916-9. PubMed ID: 10542139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gamma-secretase--intramembrane protease with a complex.
    Wolfe MS
    Sci Aging Knowledge Environ; 2003 Mar; 2003(11):PE7. PubMed ID: 12844518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease.
    Steiner H; Capell A; Leimer U; Haass C
    Eur Arch Psychiatry Clin Neurosci; 1999; 249(6):266-70. PubMed ID: 10653281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease.
    Selkoe DJ
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11039-41. PubMed ID: 11572965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals.
    Li T; Ma G; Cai H; Price DL; Wong PC
    J Neurosci; 2003 Apr; 23(8):3272-7. PubMed ID: 12716934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism.
    Tomita T
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):295-300. PubMed ID: 18038124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling.
    Berezovska O; Jack C; McLean P; Aster JC; Hicks C; Xia W; Wolfe MS; Kimberly WT; Weinmaster G; Selkoe DJ; Hyman BT
    J Neurochem; 2000 Aug; 75(2):583-93. PubMed ID: 10899933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
    Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
    Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of proteolysis in Alzheimer's disease.
    Hooper NM; Trew AJ; Parkin ET; Turner AJ
    Adv Exp Med Biol; 2000; 477():379-90. PubMed ID: 10849764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of the interaction between presenilin 1 and the substrate of gamma-secretase to produce Abeta in insect cells.
    Pitsi D; Kienlen-Campard P; Octave JN
    J Neurochem; 2002 Oct; 83(2):390-9. PubMed ID: 12423249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A portrait of Alzheimer secretases--new features and familiar faces.
    Esler WP; Wolfe MS
    Science; 2001 Aug; 293(5534):1449-54. PubMed ID: 11520976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease.
    Alves da Costa C; Sunyach C; Pardossi-Piquard R; Sévalle J; Vincent B; Boyer N; Kawarai T; Girardot N; St George-Hyslop P; Checler F
    J Neurosci; 2006 Jun; 26(23):6377-85. PubMed ID: 16763046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. gamma-Secretase: characterization and implication for Alzheimer disease therapy.
    Xu M; Lai MT; Huang Q; DiMuzio-Mower J; Castro JL; Harrison T; Nadin A; Neduvelil JG; Shearman MS; Shafer JA; Gardell SJ; Li YM
    Neurobiol Aging; 2002; 23(6):1023-30. PubMed ID: 12470798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. γ-Secretase and its modulators: Twenty years and beyond.
    Xia W
    Neurosci Lett; 2019 May; 701():162-169. PubMed ID: 30763650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease.
    Evin G; Sharples RA; Weidemann A; Reinhard FB; Carbone V; Culvenor JG; Holsinger RM; Sernee MF; Beyreuther K; Masters CL
    Biochemistry; 2001 Jul; 40(28):8359-68. PubMed ID: 11444983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathogenesis of Alzheimer's disease: implications from amyloid research front].
    Iwatsubo T
    Rinsho Shinkeigaku; 2004 Nov; 44(11):768-70. PubMed ID: 15651286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The gamma-secretase complex: machinery for intramembrane proteolysis.
    Iwatsubo T
    Curr Opin Neurobiol; 2004 Jun; 14(3):379-83. PubMed ID: 15194119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the development of gamma-secretase inhibitors.
    Josien H
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.